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Background: To characterize cathepsin K (CTSK) mutations in a group of patients with pycnodysostosis, who
presented with either short stature or atypical fractures to pediatric endocrinology or dysmorphic features to
pediatric genetics clinics.
Methods: Seven exons and exon/intron boundaries of CTSK gene for the children and their families were amplified
with PCR and sequenced. Sixteen patients from 14 families with pycnodysostosis, presenting with typical
dysmorphic features, short stature, frequent fractures and osteosclerosis, were included in the study.
Results: We identified five missense mutations (M1I, I249T, L7P, D80Y and D169N), one nonsense mutation (R312X)
and one 301 bp insertion in intron 7, which is revealed as Alu sequence; among them, only L7P and I249 were
described previously. The mutations were homozygous in all cases, and the families mostly originated from the
region where consanguineous marriage rate is the highest. Patients with M1I mutation had fractures, at younger
ages than the other pycnodysostosis cases in our cohort which were most probably related to the severity of
mutation, since M1I initiates the translation, and mutation might lead to the complete absence of the protein. The
typical finding of pycnodysostosis, acroosteolysis, could not be detected in two patients, although other patients
carrying the same mutations had acroosteolysis. Additionally, none of the previously described hot spot mutations
were seen in our cohort; indeed, L7P and R312X were the most frequently detected mutations.
Conclusions: We described a large cohort of pycnodysostosis patients with genetic and phenotypic features, and,
first Alu sequence insertion in pycnodysostosis.
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Pycnodysostosis is a rare autosomal recessive disorder char-
acterized by short stature, acroosteolysis of the distal pha-
langes, clavicular dysplasia, osteosclerosis with increased
bone fragility, and delayed closure of sutures [1-6]. To date,
less than 200 cases with equal sex distribution have been
reported worldwide and, estimated prevalence is 1 to 1.7
per million [6]. The gene locus responsible for the Pycnody-
sostosis had been mapped to human chromosome 1q21 by
genetic linkage analysis [7,8] and the gene encoding cathep-
sin K (CTSK) was identified through the positional cloning
strategy [9]. Cathepsin K is a lysosomal cysteine protease* Correspondence: serap.turan@marmara.edu.tr
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involved in the degradation of bone matrix proteins, type I
and type II collagen, osteopontin, and osteonectin at low
pH [10,11]. The CTSK genomic DNA spans 12 kb and con-
tains 8 exons and 7 introns. The translation initiation
codon methionine (Met1) is located in exon 2, whereas the
termination codon is located in exon 8. cDNA of CTSK
encodes 329 amino acid protein including 15-amino acid
signal peptide encoded by part of exon 2, a 99 amino acid
proregion encoded by the parts of exon 2, exon 3, and the
part of exon 4 and, 215-amino acid mature active enzyme
encoded by the parts of exon 4, exon 5, 6, 7, and 8 [12].
CTSK is synthesized as an inactive precursor protein,
and requires removal of its N-terminal proregion for ac-
tivation [13]. This autocatalytic process occurs under a
low-pH environment [14,15].Ltd. This is an Open Access article distributed under the terms of the Creative
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fied in the CTSK gene and these mutations are nonsense,
missense, frameshift, splice site mutations, small deletions
and insertions. Majority of the mutations are located at
the mature active domain of CTSK protein [6].
In this study, the coding region and exon/intron bound-
aries of the CTSK gene were analyzed for mutations in
sixteen children from fourteen families with Pycnodysosto-
sis. Five missense mutations (M1I, I249T, L7P, D80Y and
D169N), one nonsense (R312X ) and one insertion mutation
were identified. Five of the described mutations are novel
(M1I, D80Y, D169N, R312X and insertion mutations).
Methods
Patients
Sixteen patients from 14 families were studied. Patients #1-
I and #1-II are distant cousins, while patients #13-II.1
and #13-II.3 are the sisters. Nine patients were evaluated in
the Pediatric Endocrinology Clinics in Istanbul and
Erzurum due to short stature, while seven patients were re-
ferred to a Pediatric Genetic Unit in Ankara for dysmorphic
features. The diagnosis was based on their phenotypic
and radiographic evaluation. The clinical features of the
patients are summarized on Table 1, in which the num-
ber of fractures and height standard deviation scores
(SDS) are representing data at the time of presentation.
Figure 1 shows typical acroosteolysis and osteosclero-
sis, which are the most prominent radiological and mor-
phological feature of the disease. However, patients #8
and #13.II did not show any acroosteolysis, osteosclero-
sis and typical facial feature leading to diagnosis. As an
additional finding, one of the patients had Arnold
Chiari malformation (Patient #6) and patient #8 had
craniosynostosis.
Marmara University ethics committee approved the
study and, written informed consents were obtained
from the patients and parents for the genetic studies.
Molecular genetic analysis
DNA isolation and specific exon and exon/intron boundary
PCR
Genomic DNAs were isolated from blood samples of the
patients and their families according to salting out method
[16], and kept at 4°C. The exons 2–4 and 6–7 together,
and exon 5 and 8 separately and their flanking splice sites
were amplified by polymerase chain reaction (PCR) using
the primers shown in Additional file 1: Table S1.
PCR reactions were performed in presence of 500 ng
genomic DNA, 1X PCR buffer, 1U taq polymerase, 200 μM
each deoxynucleotide triphosphate, 0.25 μM each primer
and, cycling conditions for exons 2-4, 5, 6-7 and 8 were
(94°C, 3 min)x1; 94°C, 30 sec, 54°C, 30 sec, 72°C, 45 sec)
X35; 72°C, 10 min)X1. PCR products were visualized on
2% agarose gels to rule out large deletion and insertions.DNA sequencing
The amplified PCR products for CTSK gene were puri-
fied and sequenced with direct sequencing of the DNA
Cycle sequencing System (ABI Prism kit) with the
dideoxy-chain termination method and applied on an
autosequencer (ABI Prism 377 DNA sequencer).
Data analysis
Sequencing traces were analyzed through BLAST data-
base (NCBI) and Web Map Preferences (Harvard) and,
acceptor splice site in the insertion sequence was deter-
mined by Human Splicing Finder-Version 2.4.1.Results
Seven exons and exon/intron boundaries of CTSK gene
for the children and their families were amplified with
PCR and sequenced. Five different missense mutations
were determined in the Cathepsin K gene. Patients #1-I
and #1-II were cousins and showed 3 G > A mutation lo-
cated at exon 2 and the G residue of translation initi-
ation codon ATG was converted to A (ATA). This
mutation is homozygous (Additional file 2: Figure S1A)
and is also novel. This mutation changes the translation
initiation codon and leads to no protein synthesis (M1I),
since there is no in-frame Kozak sequence in the follow-
ing exons and, significantly reduced protein synthesis in
L7P mutation, which is located in the signaling peptide
sequence, has been shown [4].
The L7P homozygous mutation was observed in pa-
tients #2, #3, #4 and #5, and this mutation was reported
previously in an Italian family [4]. L7P mutation oc-
curred by changing of the T residue of CTG codon to C
residue resulting to CCG at exon 2 (Additional file 2:
Figure S1B). This mutation was previously shown to
affect CTSK protein targeting due to disruption in signal
peptide sequence of protein [4].
The D80Y mutation was located at exon 3 of the CTSK
gene and observed in patient #6. This mutation is homozy-
gous and occurs by changing of the G residue of GAC
codon encoding D to T, creating the TAC encoding Y
(Additional file 2: Figure S1C, shown in reverse sequence C
to A). This mutation is also novel and was found at the pro-
domain of CTSK. This mutation changed highly charged
hydrophilic D to less hydrophobic bulky Y amino acid; this
probably affects protein folding of CTSK protein.
Patient #7 showed D169N mutation and this mutation
is located at exon 5. This mutation occurs by changing
of the G residue of GAT codon encoding D to A to form
AAT encoding N. This mutation is also a novel mutation
(Additional file 2: Figure S1D and Additional file 3: Figure
S2). This mutation changed highly hydrophilic, negatively
charged, D residue to uncharged amino acid N of CTSK,
and this change might be detrimental to protein folding.
A B
Figure 1 Panel A: Typical finding of acro-osteolytic distal phalanges on X-rays and wrinkled skin over the dorsa of distal fingers and
flattened and grooved nails in pycnodysostosis detected in patient 4. Panel B: Osteosclerosis without acroosteolysis detected on radiograph
of the patient #8.
Table 1 Clinical and demographic features of the patients with pycnodysostosis summarized according to mutations
Pt ID City of Origin Centers Age (F/M) Open Ant. Fontanel Acroosteolysis Fractures (n)- age (yr)* Height SDS
M1I-(3G- > A)- Exon 2
1-I Ordu Istanbul 2.7 (F) Yes Yes Cranium (1)-2.3 −3.01
1-II 6.5 (F) No Yes Femur (2)-5.4 −2.36
L7P- (20 T - > C)-Exon2
2 Ankara Ankara 32 (M) No Yes Femur (2), tibia (1) −4.3
3 Ankara Ankara 10 (M) Yes Yes Tibia (1) −3.9
4 Çorum Istanbul 11 (F) No Yes Tibia (1)-9.7 −4.8
5 Samsun Ankara 19 (M) Yes Yes Tarsal (1)-14 −3.8
D80Y-(238G- > T)-Exon 3
6 Kastamonu Istanbul 10.5 (F) No Yes Yes**-10.5 −2.31
D169N-(505G- > A)-Exon 5
7 Erzincan Erzurum 5 (M) Yes Yes No −2.2
I249T-(746 T- > C)-Exon 6
8 Sivas Istanbul 6 (F) No No No −2.6
9 Yozgat Ankara 12 (M) Yes Yes Tibia (3), clavicle (1), scapula (1)-6 −3.6
R312X-(934C- > T)- Exon 8
10 Yozgat Ankara 14 (M) Yes Yes No −4.4
11 Corum Ankara 8 (F) Yes Yes No −5.2
12 Erzincan İstanbul 9.8 (M) No Yes Tibia (3)-5 −2.12
N296fX54 (IVS7-14-15insAlu: HSU18392)-Intron 7
13-II.1 Mardin Istanbul 6.5 (F) Yes Yes No −4.64
13-II.3 1 (F) Yes No No −1.77
14 Batman Ankara 16 m (F) Yes Yes No −2.0
*The age given for fractures is the age the first fracture occurred in the patient. **Cervical vertebrate during operation for Arnold Chiari malformation.
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located at exon 6 in patients #8 and #9 and, this muta-
tion was created by changing of the first T residue of
ATT encoding I to C to form ACT encoding T amino
acid (Additional file 2: Figure S1E and Additional file 3:
Figure S2). This mutation was previously reported and
affects the hydrophobic cluster of CTSK protein result-
ing in unfolding structure of the protein [4].
R312X mutation was observed in patients #10, #11
and #12, and this mutation is homozygous and novel
(Additional file 2: Figure S1F). This mutation was caused
by changing of the C residue of CGA encoding R to T re-
sulted in TGA, stop codon on CTSK gene. Patients carrying
this mutation will have a CTSK missing 17 amino acid resi-
dues from the carboxy terminal.
Agarose gel electrophoresis results in exon 8 and its
boundaries showed that patient #13-II.1 and #13-II.3, who
were siblings, had novel homozygous insertions and, their
healthy parents and healthy siblings had one normal band
and one inserted band (Figure 2). The exact localization of
the insertion could be determined by forward and reverse
sequencing traces and the insertion was detected at intron
7 close to the exon 8. The 301 bp size of the insertion was
determined by sequencing. It was shown that the inserted

















Figure 2 Panel A: Pedigree of the family #13. Panel B: PCR of exon 8 at
showing, patient #13-II.1 & #13-II.3 were homozygous for 301 bp insertion by
family members were carriers for the insertion, due to band of both 304 and
insertion and forward (a) and reverse (b) primer sites. Panel D: Sequencing re
exon 8 of the patients #13-II.1 showing insertion starting from intron 7 after c
Alu of 301 bp in antisense direction. For nucleotides; small letters represents i
inserted segment, respectively. New splice acceptor site within the inserted seorientation. Furthermore, the insertion showed new po-
tential splicing acceptor site at position 38 of the insertion
sequence with a consensus value of 89.2%, and, consensus
value for formal (wild type) acceptor site was 87.8% on
Human Splicing Finder. This new splicing acceptor site
most probably is used for alternative splicing. The mRNA
for CTPK contains exon 2, 3, 4, 5, 6, 7, insertion and exon
8; however, the insertion sequence introduced stop codon
(TAG) after 54 unrelated amino acids in the proceeding se-
quence, based on the predicted splicing event. When ribo-
some synthesizes CTPK protein, it stops protein synthesis
in the nonsense codon on m-RNA. Thus, CTPK protein
contains all exons including part of peptide encoded by in-
sertion sequence except exon 8. However, we could not
show mutant expression and proteins with the experiments,
since no CTSK mRNA expression in the blood was de-
tected in both healthy subject and the patients.
Further analysis showed that patient #14 presented from
different center also had the same insertion and the family
denied any consanguinity with the first family.
We detected homozygous mutation in the CTSK gene
in all patients diagnosed as pycnodysostosis by clinical
features. Additionally, no other case with clinically sug-
gestive for pycnodysostosis and without any mutation in
CSTK was detected in our cohort.1  WT II.3
605 bp
304 bp
I.1   I.2   II.2   II.3 
 Patients Family members 
agarose gel electrophoresis of siblings #13-II.1 & #13-II.3 and, WT
having a single band of 605 bp size instead of 304 bp. The other healthy
605 bp size. Panel C: Schematic presentation of CTSK exon 7 & 8, 301 bp
sults from forward primer located at intron 7 and reverse primer from
tt nucleotide and following with poly (T) which belongs to the human
ntron 7, white capital letters and red capital letters represent exon 8,
gment is given in the box and stop codon as gray capital letters.
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All detected mutations in our cohort were homozygous
and the parents were consanguineous in 12 families,
explaining homozygous mutation in all families. Parental
consanguinity was denied in two families (patient #6, and
patient #9). Further extensive pedigree analysis in these
two families revealed that for patient #9, the parents origi-
nated from nearby villages. For patient #6, the paternal
grandmother of the patient originated from a neighboring
village of the mother’s family suggesting that the consan-
guinity existed in several generations back between the
parents of both families.
The patients were presented to three different centers
in Istanbul, Ankara and Erzurum, where the families
were currently residing.
As detailed in the table, the L7P and R312X mutations
were each shared by four and three families respectively,
while I249T and the Alu insertion mutations were found
in two unrelated families. This observation led us to go
back and specifically investigate where ancestors of the
families lived before their current city of residence. We
were able to detect the villages where the families immi-
grated to cities for all families. The families of #2 & #3
and, #4 & #5 for L7P, as well as #10 & #11 for R312X
and #13 & #14 for Alu insertion mutation used to live in
close villages, even these villages remained within the
border of different cities. However, families #12 for R312X
and #8 & #9 for I249T did not originate from very close
regions to other families; however, they are from the same
geographical region of the country. So far, the close prox-
imity of common mutations suggests common ancestry.
Additional file 4: Figure S3 demonstrates the geographical
distribution of all families.
Discussion
In this study, we identified seven different homozygous
CTSK mutations in sixteen Turkish children with pycno-
dysostosis from 14 families. Figure 3 shows previously de-
scribed mutations in the upper panel and the five novel
mutations described in this paper in the lower panel. All
mutations detected were homozygous and the parents
were consanguineous in twelve families. Two families,
who denied consanguinity, were later found to be originat-
ing from nearby villages. Four of the described mutations
were present in more than one family. This observation
suggests the presence of founder mutations in patients ori-
ginating from geographically close cities in Anatolia. The
founder mutations probably pooled for centuries with the
help of high consanguineous marriage rate. In fact, the re-
gions where most families originate, namely Northern and
Southeastern Anatolia have a higher percentage of consan-
guineous marriages (up to 40%) well above the average of
Turkey (21%) [17]. Furthermore, L7P and I249 mutations,
have been described previously from Italian and Spanishpatients, respectively, as a part of compound heterozygous
mutations [4]. We speculated that the mutated alleles could
originate from a common ancestry. Additionally, only one
novel mutation (V119cfsX25) has been detected previously
in two Turkish families living in nearby villages [18]. This
mutation is not detected in our cohort, the reason of this;
families in this study come from the North East region of
the country while these two families are from the Western
part of the country.
In literature, several mutations have been reported in pa-
tients with pycnodysostosis. There are 23 different missense
mutations (69.70%), three nonsense mutations (9.09%), two
frame-shift duplication mutations (6.6%) and two frame-
shift deletion mutations (6.6%), two splicing mutations,
(6.06%), and one stop codon mutation (3.03%) [6]. Distribu-
tion of reported mutations in CTSK gene showed that 70%
of mutations were found in the mature domain, 24.24%
mutation in the proregion and 6.06% mutations in the pre-
region of CTSK gene [6]. In our cohort, 71% of mutations
are missense, 14% of mutations are nonsense, while 14%
have insertion mutations. The ratio of missense and non-
sense mutations in our cohort is similar to those described
in the literature; however, the insertion mutation is novel
and noteworthy. Localization of mutations in our cohort
showed four mutations in the mature domain (57%), which
is consistent with literature showing that most mutations
are located in the mature domain. We detected two muta-
tions in the predomain and one mutation in the prodomain
of CTSK protein (Figure 3).
Intron 7–301 bp insertion mutation (IVS7-14-15insAlu:
HSU18392) is the first large insertion mutation described
in CTSK gene. It was revealed that the insertion was the
human Alu element, which is the mobile element in hu-
man genome and makes insertion all through the human
genome and mostly in intronic region. The Alu element
consist of about 280 bases in length of main body with a
short A-rich region, called as Poly(A) tail [19]. The 3’ end
of an Alu element has a longer A-rich region that plays a
critical role in its amplification mechanism [20]. Here, our
insertion segment had 20 bp of the polyadenylation site
seen as T, in antisense direction. Alu elements have a ten-
dency to integrate to the AT-rich sites of the genome i.e.
5’-TTAAAA-3’/5’-TTTTAA-3’ [21]. The poly(T) was de-
tected at the downstream of Alu insertion segment at in-
tron 7 of CSTK in our case, most probably it serves as the
insertion site for poly(A) tail for Alu sequence.
Alu insertions contribute to diseases by either disrupt-
ing a coding region or a splice signal [22,23]. In our case,
alternative splicing involving Alu elements, known as
exonization [24] and premature stop codon after unre-
lated 54 aa has been occurred.
It is estimated that new Alu insertion occurs about one
per 20 human births [25], and one in every 1000 insertions
cause a new human genetic disease [22]. Alu element
Figure 3 The schematic presentation of the CTSK gene and protein: The genomic structure of the CTSK gene with 8 exons in the top half
and the polypeptide comprising a 15-amino acid preregion, a 99-residue proregion, and a 215-amino acid mature domain in the bottom
half. A total of 33 reported mutations are shown on gene schema on the upper panel, mutation given in thick frames are hot spot mutations,
mutation detected herein with red letters and another mutation detected in Turkish families in black letters are shown on the lower panel.
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cers and polymorphisms related to common diseases
in the population [26]. Alu insertion is well described in
angiotensin converting enzyme (ACE) polymorphism, and
its relation to hypertension, diabetes and metabolic syn-
drome [27-29]. The Alu insertion in intron 16 of ACE leads
to decreased enzyme activity with more severe in homozy-
gous states [30]. This condition is very similar to our muta-
tion detected here, since both have decreased enzyme
activity.
The R241X and A277V or A277E mutations were previ-
ously described as hot spot mutations for CTSK gene [6].
However, none of these hot spot mutations have been de-
tected in our cohort.
The remarkable clinical features of patients in our co-
hort were the atypical fractures and short stature in
addition to osteosclerosis, which was present in all pa-
tients (Figure 1). Two of the patient did not show any
acroosteolysis (#8 and #13.II), although patients who were
carrying the same homozygous mutations had acroosteo-
lysis. The absence of acroosteolysis may be misleading in
these cases, and typical facial dysmorphic features and
family history let us to the diagnosis. However, in a cases
series, Pangrazio et al. detected CTSK mutations in pa-
tients with classical features of osteopetrosis, like blind-
ness, anemia or bicytopenia, splenomegaly and suggestive
pedigree of autosomal recessive osteopetrosis, by exome
sequencing. Patients in this group had osteosclerosis, but
not acroosteolysis, which is a typical and discriminative
radiological feature of pycnodysostosis [31]. Furthermore,
our patient #8, who did not have acroosteolysis, also hadthrombocytopenia and craniosynostosis; however, none of
the other patients including patient #13.II had any classical
features of osteopetrosis, other than osteosclerosis. We con-
clude that the absence of acroosteolysis does not exclude the
diagnosis of pycnodysostosis, and could be a sign of more se-
vere phenotype with the classical osteopetrotic features.
Additionally, height SDS of the patients are changing
from −1.77 to −5.2 SDS in our cohort and, it seems that
there is no specific height difference between patients car-
rying different mutations. Furthermore, height SDS of the
patient who carrying the same mutation does not show
any trend with age, since better height SDSs were detected
in older patients in M1I and R312X group. This is the first
paper studying the genotype phenotype correlation, and
no genotype phenotype correlation could be found. How-
ever, the age of the first bone fracture and probably sever-
ity of the fractures could be related to the type of protein
defect, since patients with M1I mutations were the youn-
gest patients with fractures in our cohort and, in which
translation initiation codon changed and the complete ab-
sence of CSTK protein is suggested. The youngest patient
with fractures described in literature is 10 months old, in
whom mutation analysis was not performed; however, his
two sibling with pycnodysostosis died due to the disease
suggesting the more severe phenotype and/or genotype in
that family [32].
In our cohort, we found that one pycnodysostosis pa-
tient had Arnold Chiari malformation and another had
craniosynostosis. Craniosynostosis has previously been de-
scribed in four other cases with pycnodysostosis [32-35].
More recently, Arnold Chiari malformation was reported
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phenotype of the disease [31]. So far, craniosynostosis
seems not to be a rare entity and Arnold Chiari malforma-
tion can also be seen in pycnodysostosis.
In conclusion, analyses of the CTSK gene in our pycno-
dysostosis cohort resulted in the description of five novel
mutations including one large insertion in the CTSK gene,
with a possible founder effect. The hot spot mutations
previously described (R241X and A277V or A277E) were
not detected in this cohort, indeed, L79 and R312X were
the most frequent mutation in our cohort of patients with
pycnodysostosis.
Additional files
Additional file 1: Table S1. PCR Primers for CTSK gene: The primers were
used for the amplifications of specific exons and exon/intron boundaries for
exon 2–8. F and R show forward and reverse primers respectively.
Additional file 2: Figure S1. The sequencing traces of the patients
with CTSK mutations, normal sequence shown on upper, mutated
sequence shown on lower panel. A) M1I Mutation: A normal person has
Methionine amino acid residues as translational initiation codon on CTSK
gene encoded by ATG, G residue change to A to of ATA in the patients.
B) L7P Mutation, The normal person contains Leucine (L) encoded by
CTG and the patient has proline (P) encoded by CCG created by
changing of T residue of CTG codon to C residue. C) D80Y Mutation: The
control showed GAT codon encoding Aspartic acid (D) and the patient
has TAC encoding Tyrosine (Y) created by changing of G residue of GAT
codon to T residue forming TAC codon. D) D169N mutation: A normal
person has GAT codon at positioned 169 encoding Aspartic acids
(D) and G residue of GAT was substituted with A residue to make AAT
codon encoding asparagines (N). E) I249T mutation: Isoleucine (I)
encoded by ATT found at healthy people and I249T mutation was
created by conversion of the first T residue of ATT to C to make ACT
encoding Threonine (T). F) R312X: The change of C residue of CGA
encoding Arginine (R) to T resulted in TGA resulted in a stop codon.
*Shown in reverse sequence.
Additional file 3: Figure S2. The sequence traces of the mutations I249T
and D169N. The parents are heterozygous for the mutation and the patients
are homozygous for ATT to ACT and GAT to AAT nucleotide changes.
Additional file 4: Figure S3. The mutation map of CTSK gene in Turkey
showing that the same mutation originates from the neighboring
geographical regions: Mutations are given according to the latitude of
the country where the families originally located at upper panel.
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